8 results about "Fumaric Acid Esters" patented technology

The present application relates to a combination of 5-amino-2,3-dihydro-1,4-phthalazinedione or one of its pharmaceutically acceptable salts and at least one fumaric acid ester or a pharmaceutically acceptable salt thereof. In particular, the invention relates to the use of 5-amino-2,3-dihydro-1,4-phthalazinedione sodium salt in said pharmaceutical combination. Pharmaceutical compositions and advantageous formulation techniques are disclosed.

The present application relates to a laminated film comprising a substrate and an optical functional layer, the substrate comprising a cellulose acylate having an acyl substitution degree of 2.6 to 3.0 and a sugar ester in which 70 to 100% of hydroxyl groups are substituted with acyl groups, the optical functional layer containing a polymer containing a polymerization unit of a fumaric acid ester at a proportion of 90% by mole or more, 80 to 100% of the ester portion of the polymerization unit of the fumaric acid ester being isopropyl ester, the laminated film having an out-of-plane phase difference based on a wavelength of 650 nm and a wavelength of 450 nm, and a slope of 0.040 to 0.055, and a ratio of the out-of-plane phase difference based on a wavelength of 450 nm and a wavelength of 550 nm of 1.1 to 1.9.

By using a resin composition having excellent retardation properties and transparency, a film having excellent adhesion to a substrate is provided. [Solution] A resin composition containing 80.0 to 99.9 wt % of a fumaric acid ester-based polymer containing a fumaric acid diester residue and 0.1 to 20.0 wt % of an aromatic hydrocarbon resin having a weight-average molecular weight of 5,000 or less and containing a residue unit represented by the following general formula (2): JPEG2026043089000008.jpg4769 (wherein, each R3 independently represents hydrogen or an alkyl group having 1 to 12 carbon atoms, and R4 represents hydrogen or a methyl group).

(Solution) Provides a gel-like composition comprising a vinyl chloride-based resin and a plasticizer, which exhibits a gel state at 20°C. The plasticizer is at least one selected from the group consisting of isophthalic acid esters, terephthalic acid esters, fumaric acid esters, acetylicinoleic acid esters, citric acid esters, acetyl citrate esters, adipic acid esters selected from di-2-ethylhexyl adipic acid (DOA) and diisononyl adipic acid (DINA), maleic acid esters and their derivatives, and salts thereof. Provides an electronic device comprising a first electrode and a second electrode, and a polymer layer disposed between the first electrode and the second electrode and comprising the gel-like composition.

The present invention relates to a process for the industrial-scale production of 5-{2-[benzyl-(1-(4-hydroxyphenyl)-1-methylethyl)amino]-1-hydroxyethyl}benzene-1,3-diol hemifumarate, a salt consisting of two molecules of 5-{2-[benzyl-(1-(4-hydroxyphenyl)-1-methylethyl)amino]-1-hydroxyethyl}benzene-1,3-diol and one molecule of fumaric acid, and having the following formula: 5-{2-[benzyl-(1-(4-hydroxyphenyl)-1-methylethyl)amino]-1-hydroxyethyl}benzene-1,3-diol hemifumarate is a useful intermediate in the synthesis of 5-[(1RS)-2-[(1RS)-2-(4-hydroxyphenyl)-1-methylethyl]-amino-1-hydroxyethyl]benzene-1,3-diol hydrobromide, which is used in the pharmaceutical field under the is known by the common name fenoterol hydrobromide.

Methods of using one or more fumaric acid esters or pharmacologically active salts, derivatives, analogues, or prodrugs thereof to increase expression of fetal hemoglobin (HbF) are disclosed. The methods typically include administering to a subject an effective amount of one or more fumaric acid esters optionally in combination or alternation with hydroxyurea to induce HbF expression in the subject in an effective amount to reduce one or more symptoms of a sickle cell disorder, a hemoglobinopathy, or a beta-thalassemia, or to compensate for a genetic mutation is the human beta-globin gene (HBB) or an expression control sequence thereof. Pharmaceutical dosage units and dosage regimes for use in the disclosed methods are also provided.

Provided is a novel fumaric acid ester resin that has an excellent storage modulus at high temperatures and a film that includes the fumaric acid ester resin. A fumaric acid ester resin according to the present invention includes a residue unit represented by formula (1) and a residue unit represented by formula (2).　In formula (1), R1 and R2 each independently represent an alkyl group that has a norbornane skeleton.　In formula (2), R3 and R4 each independently represent a C1–12 straight-chain alkyl group, a C3–12 branched alkyl group, or a C3–6 cyclic alkyl group.

The invention belongs to the technical field of medicines, and discloses application of fumaric acid protoicellamate in preparation of medicines for preventing and treating respiratory virus infectious diseases. The invention particularly relates to application of a natural product fumaric acid protoicellamate or a metabolite thereof in vivo as an active ingredient in preparation of drugs with broad-spectrum antiviral activity and prevention and treatment of virus infectious diseases. The invention also discloses a medicine taking the trans-butene protoicellamate or the analogue thereof as an active ingredient. The traditional Chinese medicine composition can be used for preventing and treating respiratory virus infection such as human respiratory syncytial virus (RSV), human metapneumovirus (HMPV), human rhinovirus (HRV), influenza virus, coronavirus, parainfluenza virus, measles virus, parotitis virus, rubella virus, adenovirus, cytomegalovirus, enterovirus, herpes simplex virus, varicella-zoster virus and the like; and infection of enteroviruses such as coxsackie virus, echovirus and the like can be prevented and treated, and a new drug treatment scheme is provided for clinical viral infection.